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Introduction 
The occurrence of multi-antibiotic resistant bacteria has 
become a serious clinical obstacle worldwide. Therefore, 
there is a need to much more research to develop new 
antimicrobial agents.1,2 Bacteriocins which are produced 
by bacteria are a group of bactericidal compounds of 
peptide entity.3 The widespread occurrence of bacterial 
species with bacteriocin production in microbial 
ecosystems such as the intestinal tract and epithelial 
surfaces has renewed interests in their bactericidal 
activities in recent years.4-6  
Lactic acid bacteria (LAB) are perhaps the most 
bioprospected bacteriocin producers.7-9 The LAB are 
gram-positive, facultative anaerobic, catalase-negative, 
non-spore-forming and non-motile cocci. Lactic acid-
producing bacteria from the order Lactobacilliales 
containes several genera, including Lactobacillus, 
Enterococcus, Lactococcus, Streptococcus, Leuconostoc, 
Pediococcus. These genera are of particular interest in 
terms of the widespread occurrence of them throughout 
the fermented meat, fruits, dairy products, and beverages, 
intestinal and genital tracts of both humans and animals.  
Most bacteriocins produced by LAB are exhibit activity 
only against LAB and other Gram-positive bacteria 
genetically closely related to the producer strain.10 LAB 
has been widely studied for production of antimicrobial 
peptides. These contain several well-characterized 
bacteriocins.7,11-13 Four classes of bacteriocins have been 
defined based on their molecular mass, structure, and 
thermo stability.3 Class I bacteriocins includes 
lantibiotics, which are small post-translational modified 
peptides of 5 kDa characterizing by the presence of 
unusual amino acids lanthionine and methyl lanthionine. 
Nisin is a classic example of class I bacteriocins. Class II 
bacteriocins include a large and heterogeneous group of 
heat stable non-lanthionine-containing peptides of <10 
kDa. Class III bacteriocins are large heat-labile proteins 
of >30 kDa. Class IV bacteriocins include complex 
glycoproteins and lipoproteins.3  
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Abstract 
Purpose: Because of the emergence of multi-antibiotic resistant bacteria, a number of 
infectious diseases have become a major concern to treat in health care services worldwide. 
This situation is worsened by the fact that very limited progress has been made in 
developing new and potent antibiotics in recent years. In this context antimicrobial peptides 
(AMPs) represent new potential therapeutic compounds with bactericidal or bacteriostatic 
activity against closely related bacterial strains.  
Methods: In this study, a collection of enterococci (n=170) from clinical sources were 
investigated for their potential to inhibit multiresistant nosocomial enterococci from Iranian 
hospitals.  
Results: Four isolates produced antimicrobial peptides that inhibited all the antibiotic 
resistant enterococci. This included three Enterococcus faecium isolates producing 
combinations of enterocin A, B and L50 AB. The most potent antagonism was produced by 
E. faecalis HO91. Purification and subsequent characterization by MALDI-TOF MS, 
Edman degradation and DNA-sequencing revealed that the antimicrobial compound was 
Hiracin. The purified Hiracin was evaluated for antibacterial activity against 12 
multiresistant enterococcal isolates from clinical samples. The results demonstrated that 
Hiracin is highly effective towards enterococci which were resistant even to antibiotics 
from four distinct classes.  
Conclusion: The present research addresses Hiracin as a promising alternative to 
conventional antibiotics in treatment of multiresistant enterococcal infections.  
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Bacteriocinogenic LAB and bacteriocins are now being 
considered for a variety of antimicrobial uses as 
therapeutic agents, food additives (preservatives) and 
starter cultures to control food borne pathogenic 
microorganisms.1,14 This report describes the purification 
and characterization of a peptide from E. faecalis with 
antibacterial activity against clinically isolated multi-
antibiotic resistant enterococci.  
 
Materials and Methods 
Bacterial isolation and identification  
Blood samples obtained as part of regular diagnosis and 
treatment procedures of hospitalized patients from 
different hospitals of Orumiyeh were referred to our 
laboratory in school of pharmacy, Tabriz University of 
medical sciences (TUMS). Identification of enterococci 
was performed according to Manual of Clinical 
Microbiology.15 Samples were suspended and incubated 
in Bile Esculin broth for 24 h at 37 ºC. In the next step, 
20 µL of culture were surface plated on Bile Esculin 
sodium azide agar. The plates were then incubated at 
37°C for 16 to 18 h and single black colonies were saved 
in 30% glycerol at -80 ºC as stocks. 
 
Screening for bacteriocin production 
Isolated Enterococcus strains were evaluated for 
antagonistic activity against different indicator strains as 
Staphylococcus aureus, Listeria monocytogenes, Li. 
innocua, Lactobacillus sakei, E. faecalis, E. faecium and 
E. hirae which were obtained from PTCC (Persian Type 
Culture Collection) and LMGT (Norwegian University 
of Life Sciences) collections. The antagonistic activity of 
the bacteriocin was evaluated by a spot agar method of 
Zheng and Slavik.16 Briefly, a single colony of each 
Enterococcus spp. strains was spotted onto a previously 
seeded agar plate. Plates were then incubated for 24 to 48 
h at 30 °C. The antibacterial activity of the isolates was 
evaluated by measuring the diameters of visible zones of 
inhibition against indicator strains. 
The amount of antimicrobial activity of bacteriocins was 
quantified with microtiter plate assay.17,18 First, 100 μl 
media broth was added to each well in the microtiter plate 
before 100 μl of a each fraction to be tested for 
antimicrobial activity was added to the wells of column 1. 
In the next step, two-fold serial dilutions were made in 
each column. Subsequently, 100 μl of 20x diluted 
overnight indicator culture was added to each well. Lastly, 
the microtiter plate was incubated under conditions 
appropriate for the relevant indicator, and amount of 
growth was measured by reading optical density at 620 nm 
in a microtiter plate reader. One bacteriocin unit (BU) was 
defined as the reciprocal of the highest dilution exhibiting 
growth inhibition of indicator strain by 50% under the 
assay conditions (200-μl culture volume). 
 
Genotypic differentiation of bacteriocin producing 
(Bac
+
) isolates 
Total DNA was prepared by the method described 
previously19 and stored as PCR template in the genotypic 
identification method at -20 °C. PCR amplifications was 
performed on a thermal cycler (Eppendorf AG, 
Hamburg, Germany) in a final volume of 25 µL 
containing 250 ng of DNA as template; 1 µL of each 
oligodeoxynucleotide primer set; 2 µL of 10 × PCR 
buffer (Cinnagen), 200 µmol (each) dATP, dCTP, dGTP, 
and dTTP (Cinnagen); 2.5 mmol MgCl2; and 1 U of Taq 
DNA polymerase (Promega). The cycles used were 95 
°C for 4 min for the first cycle; 95 °C for 45 s, 30 s at 54 
°C (for Enterococcus-specific primers),20 56 °C (for 
species-specific primers)21 and 72 °C for 1 min for the 
next 35 cycles; and 72 °C for 10 min for the last cycle. 
The three of PCR primers used are listed in Table 1. PCR 
products were resolved by electrophoresis on a 1.5% 
agarose gel electrophoresis (Hoefer scientific 
instruments). 
 
PCR detection of bacteriocin structural genes 
PCR test was performed to investigate whether structural 
genes of well-known enterocins among enterococci were 
present in the bacteriocinogenic isolates. The primers 
used in this study are listed in Table 1. Plasmid or Total 
DNA was extracted as described before.19 All the PCR 
reactions were carried out in a 25 µL reaction volume 
which consisted of 12.5 µL 2x PCR Master Mix 
(Cinnagen), 25 pmol of each primer, and 20-50 ng of 
template DNA. In the case of enterocin P (entP),22 
bacteriocin AS-48 (bacAS-48), bacteriocin 31 (bac31)23 
and enterocin L50A/B (entL50A/B),24 the reaction 
conditions were 4 min denaturation at 94 ºC, followed by 
40 cycles of 45 s at 95 ºC, 30 s at 56 ºC, and 35 s at 72 
ºC; this was followed by 10 min at 72 ºC and a cool 
down to 4 ºC. For enterocin A (entA)22 and enterocin Q 
(entQ),25 58 ºC and enterocin B (entB),22 bacteriocin 
1071 (bac1071), enterolysin A (enlA), and cytolysin 
(cyl),24 the annealing temperature was 60 ºC. Amplified 
PCR fragments from these reactions were separated by 
1% agarose gel electrophoresis, specific band were 
extracted from the agarose gel and purified. Enterocin 
sequences were determined by direct sequencing of PCR 
products. 
  
Partial purification of bacteriocins from culture 
supernatants 
Cell free supernatants of the bacterial strain producing 
the largest inhibition zones were prepared by removing 
the bacteria by centrifuging the 16 h cultures for 10 min 
at 10,000 g. In the first step, the supernatant containing 
bacteriocins were concentrated by ammonium sulphate 
(40%) precipitation. The protein pellets resulted from 
centrifugation at 15,000 g for 30 min (4 ºC)26 were 
dissolved in a small portion of potassium phosphate 
buffer (pH 7.0) and filter sterilized. 
 
Enzyme, pH and heat stability of partially purified 
bacteriocin 
The influence of enzymes, pH and heat on bacteriocin 
activity was determined by agar spot method against Li. 
innocua as indicator strain. Untreated bacteriocin served 
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as the control. The stability of bacteriocin to the 
following enzymes was evaluated by using spot test at 37 
ºC for 24 h: proteinase K (900 U/ mL), trypsin (5 mg/ 
mL) and catalase (2 mg/ mL).  
To evaluate the thermal sensitivity of the antimicrobial 
substances, the bacteriocin solution was checked to 
exposure for 10 min at 100 ºC. Furthermore, the stability 
of bacteriocin in different pH value was evaluated by 
adjusting the pH of partially purified bacteriocin to 2.0, 
4.0, 6.0, 8.0 and 10.0 using 5 M HCl and 8 M NaOH. 
After incubation for 1 h and 6 h at room temperature and 
readjusting the pH of treated partially purified 
bacteriocin to acidic pH, the residual activity was 
assayed. 
 
Table 1. List of primer pairs used in PCR reactions and expected product size 
Primer Sequence (5΄-3΄)                                                        Fragment size (bp) Primer Reference 
Enterococcus specific                
f:  TACTGACAAACCATTCATGATG  
r:  AACTTCGTCACCAACGCGAAC                                  
112 (Ke et al., 1999) 
Enterococcus faecalis                 
f:ATCAAGTACAGTTAGTCTTTATTAG 
r:  ACGATTCAAAGCTAACTGAATCAGT 
941 (Kariyama et al., 2000) 
Enterococcus faecium                                                   
f:  TTGAGGCAGACCAGATTGACG     
r:  TATGACAGCGACTCCGATTCC                     
658 (Kariyama et al., 2000) 
Enterocin A                          
f:   AAATATTATGGAAATGGAGTGTAT 
r:   GCACTTCCCTGGAATTGCTC 
155 (du Toit et al., 2000) 
Enterocin B                          
f:   GAAAATGATCACAGAATGCCTA     
r:   GTTGCATTTAGAGTATACATTTG                                         
201 (du Toit et al., 2000) 
Enterocin P                           
f:   TATGGTAATGGTGTTTATTGTAA    
r:   ATGTCCCATACCTGCCAAAC                                          
121 
(du Toit et al., 2000) 
Enterocin Q 
f:  ATGAATTTTCTTAAAAATGGTATCGCAAAA   
r:   TTAACAAGAAATTTTTTCCCATGGCAAG                                                
105 (Brandao et al., 2010) 
Bacteriocin 31                      
f:  CCTACGTATTACGGAAATGGT       
r:   GCCATGTTGTACCCAACCATT                                              
248 (De Vuyst et al., 2003) 
Enterocin L50A/B                                       
f:  TTGGGTGGCCTATTGTTAAA   
r:  TCTATTGTCCATCCTTGTCCA                         
224 (Solheim et al., 2009) 
Bacteriocin 1071                  
f:  ATGCTGTAGGTCCAGCTGC       
 r:  TTTCCAGGTCCTCCACCAGT                      
219 (Solheim et al., 2009) 
Bacteriocin AS-48                
f:  GAGGAGTATCATGGTTAAAGA  
r:  ATATTGTTAAATTACCAA                                             
339 (De Vuyst et al., 2003) 
Enterolysin A                       
f:  CGCAGCTTCTAATGAGTGGT   
r:  CATACACACTGCCATTTCCA                          
161 (Solheim et al., 2009) 
Cytolysin                              
f:  TGGCGGTATTTTTACTGGAG 
r:  TGAATCGCTTCCATTTCTTC                   
250 (Solheim et al., 2009) 
Hiracin 
f:  TGTCTAGCTGGCATCGGTACAG 
r:  TACCTTCTAGGTGCCCATGGAC 
170 This study 
 
Purification of the E. faecalis HO91 antimicrobial agent 
One L cell free supernatant of an overnight culture of 
strain E. faecalis HO91 was precipitated with ammonium 
sulphate and dissolved in 100 mL of dH2O. The sample 
was then filtering sterilized through 0.22 µm membrane 
filter and pH adjusted to about 3.0 using 1 M HCl. 
Comparison of minimum inhibitory concentration (MIC) 
towards the pediocin sensitive E. faecalis LMGT 2708 
and its resistant descendant LMGT 3348 was used to 
check whether E. faecalis HO91 produced a ClassIIa 
bacteriocin.  
The bacteriocin was then more purified by cation-
exchange chromatography. Five mL SP sepharose Fast 
Flow (Amersham Biosciences, Uppsala, Sweden) was 
applied in filtration bed columns, to bind to the positive 
net charge proteins/peptide molecules such as class IIa 
bacteriocins. The SP sepharose column was washed with 
100 mL dH2O then equilibrated to a pH of 3 using 10 
mmol acetic acid. Then, the sample was applied to the 
column by the rate of approximately 1 mL/min, in the 
following stage, washing by 20 mmol phosphate buffer 
pH 6.8. Next, the sample was eluted a gradient 
concentration of 0.1 M, 0.3 M, 1.0 M and 5.0 M NaCl. 
The activity of all samples was checked and they kept at 
4 °C for further analysis.  
The bacteriocin was further purified by applying the 
sample to the Äkta purifier FPLC system. The most 
active fraction (observed on the microtiter assay) was 
first diluted to a total volume of 50 mL in dH2O and 
applied to the reverse phase column (ResourceTM RPC 3 
mL) with the rate of 2 mL/min. Then, the gradient 
proportion 20-60% was generated by 0.1% TFA 
(Trifluroacetic acid) in water and 0.1% TFA with 
isopropanol at flow rate of 1 mL/min to elute the purified 
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bacteriocin. Fractions showing candidate peaks on the 
chromatogram were assayed for antimicrobial activity 
against indicator LMGT 2708, 2785 and 3348 on a 
microtiter plate. The protein concentrations of pooled 
fractions used for subsequent purification steps were 
measured at 280 nm by NanoDrop spectrophotometer.  
 
Mass Spectrometry 
To determine the precise molecular weight of purified 
peptide (bacteriocin), the fraction with high antimicrobial 
activity from reverse phase chromatography was 
concentrated about 20 times by speed vacuum and 
subjected to Matrix Assisted Laser Desorption 
/Ionization- Time Of Flight mass spectrometry (MALDI-
TOF). The peptide mass homology search was done 
through the http://au.expasy/org proteomics server and 
the MultiIdent tool, where molecular weight of all 
published peptides and proteins are available. 
 
Edman degradation (N-terminal amino acid sequencing) 
The amino acid sequence of 50 fold concentrated 
purified bacteriocin was determined by Edman 
degradation (Alphalyse A/S, Denmark). The primary 
amino acid sequence was entered into BLAST27 to search 
for peptides with similar sequences. 
 
DNA-sequence analysis of Hiracin structureal gene in E. 
faecalis HO91  
Nucleotide sequence of E. faecium T8 which contained 
Hiracin (bacteriocin T8) structural gene was reported in 
GeneBank database Accno DQ402539.1. Forward and 
Reverse primers TGTCTAGCTGGCATCGGTACAG 
and TACCTTCTAGGTGCCCATGGAC respectively 
(Table 1) were designed to amplify a 170 bp fragment 
containing the hiracin structural gene hirA. DNA-
sequencing was performed of gel purified PCR-
amplicon. 
 
Determination of antibiotic resistance among clinical 
enterococci 
The resistance patterns of 38 of 170 clinical enterococcal 
blood isolates which randomly selected were determined 
by soft agar overlay disc diffusion assay after 24 h 
incubation of plates at 37 ºC as recommended by 
National Committee for Clinical Laboratory Standards.28 
The antibiotic-containing disks (Himedia) used were 
ampicillin (Amp) 10 µg, chloramphenicol (Chl) 30 µg, 
ciprofloxacin (Cip) 5 µg, erythromycin (Ery) 15 µg, 
gentamicin (Gen) 10 µg, streptomycin (Stp) 10 µg and 
vancomycin (Van) 30 µg.  
 
Evaluation of sensitivity of multi-antibiotic resistant 
enterococci to Hiracin 
The Minimum inhibitory concentration (MIC) of purified 
Hiracin was determined towards 12 antibiotic resistant 
enterococcal strains using the microtiter assay as 
described previously. The MIC is the concentration of 
bacteriocin needed to obtain 50% inhibition of growth.  
 
Results and Disscussion 
Bacteriocin production is prevalent among clinical 
enterococci in Iran  
A total of 170 clinical blood isolates phenotypically 
classified as Enterococcus spp. were investigated for 
their ability to produce bacteriocins by agar spot method. 
A total of 32 (18.8 %) of the evaluated isolates exhibited 
inhibitory activity towards E. faecalis, E. faecium, E. 
hirae, Li. monocytogenes, and Li. innocua. Surprisingly, 
E. faecium were the predominant strain, 88% (28 of 32) 
and the remaining isolates were E. faecalis. This 
encouraged us to investigate these isolates further for 
efficient antimicrobials. 
Amongst these, 4 isolates (HS8, HO9, HO87 and HO91) 
displayed very large inhibition zones on agar and the 
highest antimicrobial activity in liquid broth media 
against the previously mentioned indicators. As the 
strong antilisterial and antienterococcal activity is 
consistent with the expression of known bacteriocins 
including class IIa, regularly found among 
enterococci,29,30 the isolates were investigated for 
presence of known bacteriocin structural genes.  
 
Genotyping of Bacteriocin producing isolates and PCR 
detection of known enterocin genes  
Four Bac+ isolates with highest antimicrobial activity 
were further identified by PCR as E. faecium (HS8, HO9 
and HO87) and E. faecalis (HO91) using Enterococcus 
genus and species specific primers (results not shown). 
The purified DNAs of the 4 bacteriocin producer strains 
(HS8, HO9, HO87 and HO91) were investigated for the 
presence of ten known structural genes encoding 
bacteriocins (Table 1) by PCR. The results showed that 
all three E. faecium strains (HS8, HO9 and HO87) 
harbored the enterocin A, B and L50A/B genes, while 
presence of enterolysin A and cytolysin genes were also 
detected in HO9 and HO87. E. faecalis HO91 carried 
only the enterolysin A structural gene. None of the Bac+ 
strains harbored enterocin Q, P, AS-48, 1071A/B or 
bacteriocin 31 structural genes. This is in line with 
previous studies showing that entA; enlA and entL50A/B 
are mostly detected among enterococcal isolates 
originated from blood and feces.31,32  
 
Biochemical stability of partially purified bacteriocin  
Acid production is probably the major mechanism of 
antimicrobial action among LAB; however enterococci 
are not as efficient acid producers as other members of 
LAB. On the other hand, they are potential bacteriocin 
producers and can antagonize competing bacteria by 
their potent antimicrobial peptides.33,34  
As shown in Table 2, the partially purified (concentrated) 
antimicrobial substances were sensitive to proteinase K 
and trypsin; in addition the activity retained after 
treatment with catalase which these two features 
confirmed the proteinaceous structure of antimicrobial 
agents. LAB such as enterococci, lactobacilli and 
bifidobacteria can kill or inhibit the growth of pathogenic 
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bacteria by producing antimicrobial agents like lactic 
acid, hydrogen peroxide and bacteriocins.  
 
Table 2. Effect of various treatments on the activity of the 
bacteriocins produced by selected enterococcal strains 
Treatment a 
Residual activity of antimicrobial 
agents after treatments c 
HS8 HO9 HO87 HO91 
En
zy
m
e Catalase + + + + 
Trypsin - - - - 
Proteinase K - - - - 
p
H
 
2.0  (1 h at RT)b + + + + 
2.0   (6 h at RT) + + + + 
4.0   (1 h at RT) + + + + 
4.0   (6 h at RT) + + + + 
6.0   (1 h at RT) + + + + 
6.0   (6 h at RT) + + + + 
8.0   (1 h at RT) + ↓ ↓ + 
8.0   (6 h at RT) ↓↓ ↓↓ ↓↓ ↓↓ 
10.0 (1 h at RT) + ↓ ↓ + 
10.0 (6h at RT) ↓↓ ↓↓ ↓↓ ↓↓ 
H
e
at
 
60 °C (30 min) + + + + 
100 °C (10 min) + + + + 
a 
Determined by spot-on-lawn method using Li. Innocua  LMGT 
2785 as an indicator microorganism;  
b 
RT= room temperature;  
c 
+ = Presence of activity; - = Absence of activity;  
↓ = Reduction in activity; ↓↓ = Serious reduction in activity 
 
It is seen from Table 2 that the stability of pH treated 
bacteriocin was detected up to pH 8.0. In pH 8.0 and 
10.0, losses in the inhibitory activity started to be seen 
for two strains at room temperature incubation for 1 h. 
When the treated bacteriocins (pH 8.0 and 10.0) were 
incubated for 6 h at room temperature, bacteriocins 
activity were dramatically reduced. This feature can be 
attributed to the solubility of the bacteriocins produced 
by Bac+ strains under their Isoelectric points (8.0-10.0).35  
 Interestingly, the activity was not significantly affected 
by heating at 60 ºC and 100 ºC for 30 and 10 min, 
respectively. Heat stability is one of the main 
characteristic features of many bacteriocins and stable 
cross-linkages, presence of strong hydrophobic regions 
as well as high glycine content are factors contributing to 
their heat resistance.35 Residual antimicrobial activity 
was determined against Li. Innocua LMGT 2785 by the 
agar spot method. 
 
Purification of the antimicrobial substance produced by 
E. faecalis HO91 
E. faecalis HO91 showed noticeable zones of inhibition 
on the spot on the lawn assay against applied indicator 
strains. The substance with antimicrobial activity were 
protease sensitive, as well as stable at pH 2.0 and 100 °C 
for 10 minutes. Furthermore, the results of PCR 
screening showed that HO91 only possessed bacteriocin 
structural gene of enterolysin A. As enterolysin A 
belongs to the class III, the large and heat-labile 
bacteriocins;
36
 hence substantial reduction in 
antimicrobial activity after boiling at 100 ºC was 
inevitable. However, no reduction in the inhibition 
activity of partially purified bacteriocin was observed, so 
it could be concluded that there was no expression for 
enterolysin A. Then, the antimicrobial activity of the 
ammonium sulphate precipitate of HO91 culture 
supernatant was tested against indicators LMGT 2708 
and its pediocin-resistant mutant strain LMGT 3348 
(2708 RS), the latter is resistant to all class IIa 
bacteriocin. This was performed to determine whether 
the produced substance was from pediocin family (class 
IIa bacteriocin). The results indicated that the precipitate 
of HO91 only could inhibit the growth of 2708 but not 
2708 RA. Hence; based on the above described results, 
the antimicrobial substance was considered a member of 
pediocin-like bacteriocin. Briefly, the bacteriocin was 
purified using SP-sepharose ion exchange 
chromatography, followed by reverse phase 
chromatography (RPC 3). Table 3 briefly describes the 
result of each purification stage of the bacteriocin. 
Interestingly, reverse phase chromatography (RPC) gave 
a pure and distinct peak with absorbance at both A214 and 
A280 (Figure 1). 
 
Table 3. Purification of the E. faecalis HO91 bacteriocin 
Fraction Vol a (ml) Activity (BU/ml) Protein (mg pr/ ml) Sp.Act.b (BU/ mg pr) Total Activity (BU) Yeild (%) 
Culture Supernatant 1000 800 20.3 39.4 800000 100 
ASPc 100 25600 14.5 1765.5 2560000 320 
Cation Exchange Ch
d
. 20 1600 0.73 2191.8 32000 4 
RPCe-3-1 1 51200 ND
f - 51200 6.4 
RPC-3-2 0.5 51200 0.18 284444 25600 3.2 
a
 Vol= volume 
b
 Sp. Act. = specific activity 
c 
ASP= ammonium sulphate precipitate 
d 
Ch= chromatography 
e 
RPC= reverse phase chromatography 
f 
ND= Not determined 
 
MALDI-TOF molecular weight determination and 
peptide mass homology search 
A fraction containing the purified antimicrobial 
compound from the 2nd RPC was used for further 
biochemical characterization. The monoisotopic 
molecular weight was determined by MALDI-TOF MS 
to 5088.9 Da (in Figure 2). Performing a peptide mass 
homology search (MultiIdent tool Expasy) produced one 
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significant hit, the bacteriocin Hiracin (bacteriocin T8) 
with the average molecular weight of 5094 Da. Hiracin is 
a class IIa bacteriocin which was isolated from both E. 
hirea and E. faecium previously.37,38 The purified peptide 
was sent for sequencing because of two reasons; firstly, 
the difference in peptide mass (about 6 Da) and 
secondly, the fact that determined producer strains were 
different from ours (E. faecalis HO91). 
 
 
Figure 1. Chromatogram of the final reversed phase purification 
of Hiracin. Solid line: mAU280 nanometers; Dotted line: % 2-
propanol 
 
 
 
Figure 2. MALDI-TOF analysis of purified bacteriocin, 
corresponding to monoisotopic molecular weight of Hiracin 
(5089.9 m+1/z) and doubly charged ion (2545.1 m+2/z). 
 
N-terminal amino acid sequencing 
N-terminal sequencing for 48 cycles presented the 
following amino acids and nucleotides: 
A   T   Y   Y   G   N   G   L  Y   X   N   K    E    K   X  W 
  V   D  W   N   Q  A  
K   G    E    I   G    K   I    I   V   N  G  W   V  N   H  G    
P   W    A   (A/P)    R   R 
 
This sequence was identical in 41 of 44 amino acids of 
Hiracin, where the 2 ‘X’ residues corresponded to 
cysteine residues. Hence it was obvious that the purified 
bacteriocin was Hiracin by the different producer strain 
(E. faecalis). 
 
Confirmation that E. faecalis HO91 is a bacteriocin T8 
(Hiracin)- producer strain 
To confirm that the bacteriocin produced by E. faecalis 
HO91 was Hiracin, a PCR analysis was performed by 
designing primers for published sequence of bacteriocin 
T8 structural gene of E. faecium T8. A 170 bp fragment 
was amplified from purified DNA of E. faecalis HO91 
and sequenced, confirming 100% identity to the hirA 
structural gene (data not shown). 
 
Assessment of antibiotic resistance patterns 
The antibiotic resistance phenotype of 38 Bac+ 
enterococcal strains was tested. In overall, 97.4% of the 
enterococcal isolates were resistant to at least one of the 
seven antibiotics applied in this survey. Interestingly, 
UDS1 was the only strain with sensitivity profile to all 
tested antimicrobial agents. 
Regarding the individual antibiotics, the enterococcal 
resistance was detected for all antimicrobial agents tested 
to different degrees (Figure 3). Majority of isolates (> 
50%) showed resistance for gentamicin (92%), 
ciprofloxacin (84%), erythromycin (76%), streptomycin 
(74%) and chloramphenicol (53%). The prevalence of 
resistance to ampicillin and vancomycin was about 
(34%) and (13%), respectively. 
 
 
Figure 3. Individual antimicrobial resistance prevalence of Bac+ 
Enterococcus spp. isolated from clinical samples, (Amp - 
Ampicillin, Chl - Chloramphenicol, Cip - Ciprofloxacin, Ery – 
Erythromycin, Gen – Gentamicin, Stp - Streptomycin, Van- 
Vancomycin) 
 
As shown in Table 4, there were seven different 
resistance patterns for seven antibiotics in this study. 
Multi-antibiotic resistance (resistance to more than one 
antibiotic) was observed in 36 (94.7%) of 38 Bac+ 
enterococcal strains. The most prevalent multi-antibiotic 
resistance profiles were detected for five antimicrobial 
agents (26.3%), followed by 21.1% to four as well as six 
and 13.2% to two. The lowest prevalence of multi-
antibiotic resistance was 5.2% and 7.9% encountered to 
the combination of three and seven antimicrobial agents 
(Figure 4).  
Emergence of enterococci which are resistant to a wide 
range of commonly used antibiotics as a cause of 
nosocomial infection is a concerning phenomenon that 
has developed in recent years.39 Indeed, our study 
revealed that there is a high-level enterococcal resistance 
to aminoglycosides, erythromycin and chloramphenicol 
among clinical isolates of enterococci. Unfortunately, 
resistance to ampicillin as well as vancomycin was also 
noticeable. 
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Another important aspect was very high proportion of 
incidence of multi-antibiotic resistance 94.7% (36 of 38) 
and surprisingly, as shown in Table 4, 7.9% (3 of 38) of 
strains were resistant to all seven antibiotics used in the 
study. 
 
Table 4. Most frequent resistance patterns of Enterococcus spp. 
isolates (Amp - Ampicillin, Chl - Chloramphenicol, Cip - 
Ciprofloxacin, Ery –  Erythromycin, Gen – Gentamicin, Stp - 
Streptomycin, Van- Vancomycin) 
Resistance 
against 
antimicrobials 
No. of 
resistant 
Enterococcus 
spp. isolates 
Most frequent resistance patterns  
(isolates) 
1 1 Gen (1) 
2 5 
Cip+ Chl (2) 
Cip+Ery (1) 
Gen+Stp (1) 
Gen+Amp (1) 
3 2 
Cip+Ery+Chl (1) 
Cip+Ery+Gen (1) 
4 8 
Cip+Ery+Gen+Stp (4) 
Cip+Ery+Gen+Chl (1) 
Cip+Gen+Stp+Chl (1) 
Ery+Gen+Stp+Amp (2) 
5 10 
Amp+Cip+ Ery+ Gen+Stp (7) 
Amp+Cip+ Ery+ Gen+Van (1) 
Amp+Gen+Van+Stp+Chl (1) 
Cip+ Ery+ Gen+Stp+Chl (1) 
6 8 
Amp+Chl+Cip+ Ery+Gen+Stp (4) 
Amp+Chl+Ery+Gen+Stp+Van (1) 
Chl+Cip+ Ery+ Gen+Stp+Van (3) 
7 3 Amp+Chl+Cip+Ery+Gen+Stp+Van(3) 
 
 
Figure 4. Antimicrobial resistance types of Enterococcus spp. 
isolated from clinical samples 
 
In vitro evaluation of Hiracin efficacy towards multi-
antibiotic resistant enterococci 
Emergence of enterococci which are resistant to a wide 
range of commonly used antibiotics as a cause of 
nosocomial infection is a concerning phenomenon that 
has developed in recent years.39 Hence, there is a need 
for alternatives to control the dissemination of large 
numbers of antibiotic resistant bacteria into the 
environment. Interestingly, bacteriocins are one of the 
best candidates which tons of papers stating the potential 
of them to inhibit the growth of objective bacteria but 
few have actually evaluated them towards multi resistant 
nosocomial bacteria. 
In this study, MIC of both partially purified and purified 
Hiracin were evaluated against L. innocua as an indicator 
strain and 11 antibiotic resistant enterococci by 
microtiter plate assay. As it is obvious from Table 5 of 
11 strains, 6 isolates (resistant from one to 4 antibiotics) 
demonstrated acceptable sensitivity to Hiracin. Based on 
the obtained data, Hiracin can be an effective bacteriocin 
against multi-antibiotic resistant enterococcal isolates. 
 
Table 5. The MIC of the partially purified and purified Hiracin against multi-antibiotic resistant enterococci 
  
Sample numbera 
L. innocua 2 11 17 18 37 38 39 49 83 90 103 
Activity (BU/ml) 
Partially purified 25600 400 400 - 1600 - 6400 3200 - - - 800 
purified 51200 800 3200 - 6400 - 25600 12800 - - - 3200 
a
2: Cip+ Chl, 11: Gen+Stp, 13: Chl+Cip+ Ery+ Gen+Stp+Van, 17: Amp+Gen+Van+Stp+Chl, 18: Cip+Ery+Chl, 37: 
Amp+Cip+Ery+Gen+Van, 38: Cip+Ery+Gen, 39: Cip+Gen+Stp+Chl, 49: Amp+Chl+Cip+Ery+Gen+Stp+Van, 83: Ery+Gen+Stp+Amp, 90: 
Amp+Chl+Ery+Gen+Stp+Van, 103: Gen 
  
Conclusion 
In conclusion, as the results of the presented experiment 
indicate an easy applicable procedure to isolate and 
purified an unknown proteinaceous substance with 
antimicrobial effect from the culture media context was 
described. In the next step, the antimicrobial activity of 
purified bacteriocin was successfully evaluated against 
multi-antibiotic resistant enterococci isolated from 
clinical samples. It would be advisable to include 
antibiotic resistant Listria into research. In addition, it 
would be interesting to check the influence of mixture of 
other bacteriocin plus Hiracin on pathogenic microbes. 
Interestingly, the obtained results could be useful in 
future approaches to control and treatment inflammatory 
conditions. 
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